Select your language
IRM: +43 316 908204-11
We are the leading address for stem cell therapy in the EU. We are not only practitioners but also a scientific research institute with an attached practice and private clinic. Since 2013, our research group has developed the key pillars of stem cell therapy and gained extensive experience in both basic research (cell counting / cell cultivation) and clinical applications for various diagnoses over more than 10 years. Every year, we publish in the top 25% of journals globally with the highest impact factors (so-called top journals). Find details of our long-standing experience in our own publications here:
We were the first to routinely examine the number of stem cells in bone marrow. This allowed us to publish the normal distribution of stem cells in the human body depending on age and diagnosis.
Result: The cell count does not decrease even in old age. Therefore, stem cell therapy can be performed even at an advanced age. In fact, this is often a preferable indication, as surgery (e.g., prosthetics, which we also perform) represents a much greater risk for this patient group.
We published the first study with the world's longest follow-up period (4 years) for BMAC therapy (stem cell therapy with mesenchymal stem cells), focusing on patients with severely worn joints (Grade III+IV).
Result: Pain, function, and activity during light and heavy household tasks and sports significantly improve. Sleep disturbances and swelling are positively affected. Improvements start from the third month and become significant and noticeable after one year. By the second year, there is further significant improvement, which remains consistently good for at least four years. Longer follow-up periods have not yet been published.
This article compares various injection therapies for treating knee osteoarthritis (OA), including corticosteroids (CS), hyaluronic acid (HA), platelet-rich plasma (PRP), and bone marrow aspirate concentrate (BMA(C)). Osteoarthritis is a common chronic joint disease that often leads to disability. Cell-based therapies such as BMA(C) show promising results. Conservative treatments such as physiotherapy and weight loss should, however, always be prioritized. CS provide short-term pain relief, while HA and PRP achieve longer-lasting improvements. BMA(C) shows significant long-term improvements starting from the second year. It is emphasized that no single therapy can be universally recommended as treatment must be individually tailored.
We have experience with virtually every bone marrow aspiration needle and collection set / centrifuge available on the market.
Result: Many devices have a CE certificate for only a single indication. The cell count varies by a factor of 10 depending on the extraction technique. Interestingly, this is rarely known in practice, which might explain the inferior results of some competitors.
As of 2024, multiple comprehensive studies (meta-analyses and reviews) from several centers worldwide support a Grade A recommendation (strongest recommendation) and Level I evidence (highest possible level) for thousands of children.
Result: On average, children improve by 25% on the ATEC score, meaning severe conditions become moderate, moderate conditions become mild, and mild conditions resolve entirely in most cases. Many children establish eye contact, start participating more in social life, and express emotions more clearly after treatment.
Orthopedics - Osteoarthritis Information Page
Orthopedics - Osteoarthritis Download
Neurology - Spinal Cord Injury Information Page
Neurology - Spinal Cord Injury Download
All scientific journals worldwide are ranked within their respective fields by the number of citations they receive (1% = best, 100% = worst in the field).
A top 25% publication appears in a journal that is among the top 25% most cited globally, indicating a very high "impact factor." For habilitation, at least two publications in top journals are required. As publications in these journals are highly sought after, the acceptance rate is only about 5%, as the quality of submitted work is anonymously reviewed by external experts.
